In a BioStock Studio exclusive, Martin Welschof, CEO of BioInvent and Wei-Wu He, Chairman and CEO of the American biopharma company CASI Pharmaceuticals, joined the program to talk about the collaboration between the two companies around the development of drug candidate BI-1206. Among other things, they discussed the reasons behind CASI choosing to partner with BioInvent, the market potential for BI-1206 and the next clinical development step for the candidate. Full Article & Video : 

https://www.biostock.se/en/2022/06/bioinvent-and-casi-on-their-collaboration/